Pages that link to "Q41716558"
Jump to navigation
Jump to search
The following pages link to Effective combinatorial immunotherapy for castration-resistant prostate cancer (Q41716558):
Displaying 50 items.
- Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment (Q33832752) (← links)
- Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine (Q39429983) (← links)
- Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer (Q39438805) (← links)
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells (Q41369044) (← links)
- Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. (Q46112903) (← links)
- Modulation of cabozantinib efficacy by the prostate tumor microenvironment (Q46493299) (← links)
- The combination of checkpoint immunotherapy and targeted therapy in cancer (Q47100314) (← links)
- Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma (Q47157214) (← links)
- Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms (Q47198804) (← links)
- De-novo and acquired resistance to immune checkpoint targeting. (Q47326952) (← links)
- Revisiting ovarian cancer microenvironment: a friend or a foe? (Q47773956) (← links)
- Myeloid-derived suppressor cells coming of age. (Q48215791) (← links)
- Dendrimer-Based Signal Amplification of Click-Labelled DNA in Situ (Q48236966) (← links)
- Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma (Q48504970) (← links)
- The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo (Q49349544) (← links)
- Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer (Q49795880) (← links)
- Neutrophil elastase in the tumor microenvironment (Q49861506) (← links)
- Potentiating prostate cancer immunotherapy with oncolytic viruses (Q50055098) (← links)
- Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy (Q50126710) (← links)
- STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. (Q52317592) (← links)
- Profiling Prostate Cancer Therapeutic Resistance. (Q52644478) (← links)
- Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. (Q52657103) (← links)
- Synthesis, Structure-Activity Relationship Studies, and ADMET Properties of 3-Aminocyclohex-2-en-1-ones as Chemokine Receptor 2 (CXCR2) Antagonists. (Q52680133) (← links)
- Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. (Q53047113) (← links)
- Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. (Q53741464) (← links)
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. (Q55249474) (← links)
- Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. (Q55343494) (← links)
- Combined immunotherapy for advanced prostate cancer: Empowering the T cell army. (Q55527258) (← links)
- Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers (Q56888738) (← links)
- Genetics and biology of prostate cancer (Q57106917) (← links)
- Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects (Q57108205) (← links)
- (Q57806035) (← links)
- (Q57806045) (← links)
- Cell death in cancer in the era of precision medicine (Q57810087) (← links)
- Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy (Q57817490) (← links)
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression (Q58561592) (← links)
- STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers (Q58594424) (← links)
- Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers (Q58694964) (← links)
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer (Q59066536) (← links)
- Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC (Q59798144) (← links)
- Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report (Q60911619) (← links)
- Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer (Q64059449) (← links)
- Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives (Q64063956) (← links)
- Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice (Q64071470) (← links)
- Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy (Q64076953) (← links)
- Prostate cancer: New model to test immunotherapy combinations (Q87618819) (← links)
- An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer (Q88697355) (← links)
- RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review (Q89484239) (← links)
- IL-1 Signaling in Tumor Microenvironment (Q89725102) (← links)
- Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy (Q90025764) (← links)